Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST [gastrointestinal stromal tumours] with a high risk of recurrence

Next Previous
X
Search
Trial Profile

Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of operable GIST [gastrointestinal stromal tumours] with a high risk of recurrence

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use

    • Most Recent Events

    • 31 May 2020 Results evaluate long-term OS of patients treated adjuvant imatinib for high-risk gastrointestinal stromal tumor, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 02 Nov 2015 Results published in the Journal of Clinical Oncology
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top